Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
Public ClinicalTrials.gov record NCT06422143. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Phase 3 Study of Pembrolizumab in Combination With Carboplatin/Taxane (Paclitaxel or Nab-paclitaxel) Followed by Pembrolizumab With or Without Maintenance MK-2870 in the First-line Treatment of Metastatic Squamous Non-small Cell Lung Cancer
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesized that pembrolizumab with maintenance sacituzumab tirumotecan is superior to pembrolizumab without sacituzumab tirumotecan maintenance with respect to overall survival (OS).
Study identification
- NCT ID
- NCT06422143
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 851 participants
Conditions and interventions
Conditions
Interventions
- Pembrolizumab Biological
- sac-TMT Biological
- Carboplatin Drug
- Paclitaxel Drug
- Nab-paclitaxel Drug
Biological · Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 9, 2024
- Primary completion
- Jan 11, 2029
- Completion
- Aug 14, 2031
- Last update posted
- Aug 30, 2026
2024 – 2031
United States locations
- U.S. sites
- 22
- U.S. states
- 13
- U.S. cities
- 20
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| CARTI Cancer Center ( Site 0006) | Little Rock | Arkansas | 72205 | Recruiting |
| Roy and Patricia Disney Family Cancer Center - Providence Saint Joseph Medical Center ( Site 0122) | Burbank | California | 91505 | Recruiting |
| Sharp Memorial Hospital ( Site 9544) | San Diego | California | 92123 | Recruiting |
| Intermountain Health Cancer Center Lutheran Hospital ( Site 0119) | Golden | Colorado | 80401 | Recruiting |
| Intermountain Health St. Mary's Regional Hospital ( Site 0116) | Grand Junction | Colorado | 81501 | Recruiting |
| Washington Hospital Center ( Site 0037) | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Mid Florida Hematology and Oncology Center ( Site 0109) | Orange City | Florida | 32763 | Completed |
| Centricity Research Columbus Cancer Center ( Site 0111) | Columbus | Georgia | 31904 | Completed |
| Northwest Georgia Oncology Centers, a Service of Wellstar Cobb Hospital ( Site 0001) | Marietta | Georgia | 30060 | Completed |
| Southeastern Regional Medical Center ( Site 0004) | Newnan | Georgia | 30265 | Completed |
| University of Chicago Medical Center ( Site 0145) | Chicago | Illinois | 60637 | Recruiting |
| Trinity Health Saint Joseph Mercy Hospital Ann Arbor ( Site 9552) | Ypsilanti | Michigan | 48197 | Recruiting |
| Allina Health Cancer Institute - Abbott Northwestern Hospital ( Site 0146) | Minneapolis | Minnesota | 55407 | Recruiting |
| John Theurer Cancer Center at Hackensack University Medical Center ( Site 0035) | Hackensack | New Jersey | 07601 | Recruiting |
| Capital Health Medical Center - Hopewell ( Site 0034) | Pennington | New Jersey | 08534 | Recruiting |
| New Mexico Oncology Hematology Consultants Ltd. ( Site 0123) | Albuquerque | New Mexico | 87109 | Completed |
| University of New Mexico Comprehensive Cancer Center ( Site 0135) | Albuquerque | New Mexico | 87131 | Recruiting |
| St Luke's University Health Network ( Site 0017) | Bethlehem | Pennsylvania | 18015 | Recruiting |
| Thomas Jefferson University - Clinical Research Institute ( Site 0147) | Philadelphia | Pennsylvania | 19107 | Recruiting |
| Memorial Hermann Cancer Center ( Site 0015) | Houston | Texas | 77030 | Recruiting |
| Oncology Consultants P.A. ( Site 0124) | Houston | Texas | 77030 | Recruiting |
| Mays Cancer Center ( Site 0132) | San Antonio | Texas | 78229 | Completed |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 194 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06422143, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Aug 30, 2026 · Synced Sep 2, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06422143 live on ClinicalTrials.gov.